search
Back to results

A Randomized Controlled Clinical Trial of Surgery Versus Conservative Treatment for Mild and Moderate-grade Nasopharyngeal Necrosis

Primary Purpose

Nasopharyngeal Carcinoma, Postradiation, Necrosis, Endoscopy Surgery, Conservative Treatment

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Curative-intent endoscopic necrectomy followed by reconstruction using the posterior pedicle nasal septum and floor mucoperiosteum flap
Conservative treatment
Sponsored by
Sun Yat-sen University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Nasopharyngeal Carcinoma, Postradiation, Necrosis, Endoscopy Surgery, Conservative Treatment

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Received radical radiotherapy for the nasopharynx;
  2. For patients with early-stage and mid-stage nasopharyngeal necrosis diagnosed for the first time by clinical symptoms, imaging examinations and pathology. The lesions are limited to the superficial tissue of the nasopharynx and the deep tissue of each wall of the nasopharynx, regardless of the exposure of internal carotid artery invasion(ICA). For those patients with ICA exposure, vascular pretreatment (vascular embolization or bypass surgery) would be performed and reassess after 2-4 weeks of vascular treatment.
  3. The patient has signed the informed notice and is willing and able to comply with the study plan visits, treatment plans, laboratory tests and other study procedures.

Exclusion Criteria:

  1. Karnofsky score ≤ 70 points or Zubrod score > 2 points;
  2. Patients with severe medical complications, insufficiency of important organs (heart, lung, liver, kidney) or neuropsychiatric disorders at the time of diagnosis.
  3. Patients with pathologically confirmed local recurrence.
  4. Cases who have received local nasal cavity and nasopharyngeal surgery in the past.
  5. Patients who cannot cooperate with regular follow-up due to psychological, social, family and geographical reasons.
  6. Other patients who are considered unsuitable for inclusion by the treating physician.

Sites / Locations

  • Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer CenterRecruiting
  • The First Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
  • The Fifth Affiliated Hospital of Guangzhou Medical UniversityRecruiting
  • The First Hospital of NanchangRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Surgery group

Conservative group

Arm Description

Prior to surgery, a bacterial cultivation for purulent nasopharyngeal secretions and drug sensitivity assays were performed to identify sensitive antibiotics to be used postoperatively. Radical endoscopic necrectomy was performed under general anesthesia using the endoscopic endonasal approach. One side flap, typically the ipsilateral side, was harvested after complete radical endoscopic necrectomy.

Patients receive debridement treatment of the necrotic tissues guided by endoscope and systematic antibiotic therapy partly under the guidance of nasopharyngeal secretion drug sensitivity test. Patients could use a common nasopharyngeal irrigation pot to wash the nasopharynx three times a day with warm boiled water or light saltwater (500 ml). If possible, patients could also received direct irrigation with an electronic nasopharyngoscopy operated by a physician. In addition, patients can receive hyperbaric oxygen therapy when conditions permit.

Outcomes

Primary Outcome Measures

The cure rate of nasopharyngeal necrosis at 3 months after enrollment
The cure rate of nasopharyngeal necrosis is defined as the complete re-epithelialization of the nasopharyngeal cavity, upon nasal endoscopic examination, and the mucosa; upon MRI examination.

Secondary Outcome Measures

The Numeric Rating Scales (NRS) of pain
The Numeric Rating Scales (NRS) of pain was used to evaluate headaches level before and within 3 months after treatment. The patients were requested to rate their level of headache on a scale from 0 to 10, with 0 being none and 10 being unbearable.
Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0) overall
The quality of life was assessed per Quality of Life Questionnaire C30 (QLQ-C30).
Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&N35)
The quality of life was assessed per Quality of Life Questionnaire Head and Neck Cancer-Specific Module (H&N35).
The cure rate of nasopharyngeal necrosis at 6 months after enrollment
Patients who was assessed as non-healing at 3 months after enrollment would receive salvage surgery. The cure rate of nasopharyngeal necrosis is reassessed at 3 months after salvage surgery.
Overall survival
The time from the date of randomization to the date of death due to any cause in an Intent-to-Treat analysis set.

Full Information

First Posted
January 25, 2022
Last Updated
February 7, 2022
Sponsor
Sun Yat-sen University
search

1. Study Identification

Unique Protocol Identification Number
NCT05228093
Brief Title
A Randomized Controlled Clinical Trial of Surgery Versus Conservative Treatment for Mild and Moderate-grade Nasopharyngeal Necrosis
Official Title
A Randomized Controlled Clinical Trial of Curative-intent Endoscopic Necrectomy Followed by Construction Using the Posterior Pedicle Nasal Septum and Floor Mucoperiosteum Flap Versus the Best Conservative Treatment for Mild and Moderate-grade Nasopharyngeal Necrosis
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2021 (Actual)
Primary Completion Date
October 30, 2023 (Anticipated)
Study Completion Date
October 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sun Yat-sen University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Post radiation nasopharyngeal necrosis is a relatively special radiotherapy sequelae after radiotherapy for nasopharyngeal carcinoma. According to the degree of its development, it can be roughly divided into three stages: mild, moderate and severe stages, corresponding to the pre-nasopharyngeal necrosis stage, the soft tissue necrosis stage and the bone necrosis stage respectively. In the past, treatment methods were limited, including anti-infection, topical nasopharyngeal drugs, etc., the efficacy was not good, the nasopharyngeal necrosis lesions progressed, and a series of serious complications occurred, such as: intracranial infection secondary to osteonecrosis, massive nasopharyngeal hemorrhage, etc. It seriously endanger the life of the patient. With the continuous development of medical technology, the means of treatment are also constantly updated, such as repeated debridement guided by nasal endoscope, modified nasopharyngeal irrigation and hyperbaric oxygen therapy, the healing rate of nasopharyngeal necrosis has improved, especially the cure rate of patients in the mild and moderate-stages can reach 54.1%-54.8%. However, there are still some patients with poor healing of nasopharyngeal wounds after treatment. Since 2004, our team has carried out a series of studies such as transnasal endoscopic nasopharyngeal resection combined with posterior pedicle nasal septum and floor mucoperiosteum flap(NSFF), and successfully achieved minimally invasive and en bloc resection of localized recurrent nasopharyngeal carcinoma. This method basically solved the problem of surgical wound healing of recurrent nasopharyngeal carcinoma. On this basis, we further applied it to the treatment of nasopharyngeal necrosis to further improve the cure rate and improve the prognosis. In addition, our retrospective study showed that compared with conservative treatment, curative-intent endoscopic necrectomy followed by reconstruction using the posterior pedicle nasal septum and floor mucoperiosteum flap can effectively prolong the overall survival time of patients and significantly improve the symptoms, but it still needs to be further confirmed by prospective clinical trials. In addition, some patients (22.2%) had necrosis of the mucosal flap after receiving surgery, which affected the healing of surgical wounds. Besides, the development of nasopharyngeal necrosis is a slow process. If nasopharyngeal necrosis removal combined with pedicled mucosal flap repair is performed prematurely, the area outside the operation area may be necrotic again. Theoretically, each patient only has the nasal septum-nasal septum mucosal flaps on both sides of the nasal septum, which means that each patient only has 2 chances of repairing the nasal septum-nasal floor mucosal flaps. Premature surgical intervention may not only lead to incomplete debridement, but also lose a valuable opportunity for mucosal flap repair. Therefore, based on the above problems, this study intends to compare the endoscopic nasopharyngeal necrosis debridement combined with pedicled mucosal flap repair versus the best conservative regimen for the treatment of early and mid-stage nasopharyngeal necrosis, to explore the prognosis of patients with nasopharyngeal necrosis. The preferred regimen, if confirmed by this study, is expected to standardize the treatment of nasopharyngeal necrosis after radiotherapy and further promote it, effectively increasing the cure rate of nasopharyngeal necrosis and improving the prognosis of patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nasopharyngeal Carcinoma, Postradiation, Necrosis, Endoscopy Surgery, Conservative Treatment

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
216 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Surgery group
Arm Type
Experimental
Arm Description
Prior to surgery, a bacterial cultivation for purulent nasopharyngeal secretions and drug sensitivity assays were performed to identify sensitive antibiotics to be used postoperatively. Radical endoscopic necrectomy was performed under general anesthesia using the endoscopic endonasal approach. One side flap, typically the ipsilateral side, was harvested after complete radical endoscopic necrectomy.
Arm Title
Conservative group
Arm Type
Active Comparator
Arm Description
Patients receive debridement treatment of the necrotic tissues guided by endoscope and systematic antibiotic therapy partly under the guidance of nasopharyngeal secretion drug sensitivity test. Patients could use a common nasopharyngeal irrigation pot to wash the nasopharynx three times a day with warm boiled water or light saltwater (500 ml). If possible, patients could also received direct irrigation with an electronic nasopharyngoscopy operated by a physician. In addition, patients can receive hyperbaric oxygen therapy when conditions permit.
Intervention Type
Procedure
Intervention Name(s)
Curative-intent endoscopic necrectomy followed by reconstruction using the posterior pedicle nasal septum and floor mucoperiosteum flap
Intervention Description
Radical endoscopic necrectomy was performed under general anesthesia using the endoscopic endonasal approach. And the reconstruction of the nasopharyngeal defect use the nasal septum and floor mucoperiosteum flap. Antibiotic therapy based on the result of bacterial cultivation before the surgery was administered for 5-7 days after surgery. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid, and endoscopic nasal cleanup was performed every 2-4 weeks until the flap was completely epithelialized and the entire defect was relined. Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery.
Intervention Type
Procedure
Intervention Name(s)
Conservative treatment
Intervention Description
Debridement guided by nasopharyngeal endoscopy and excision of the radiation-induced necrotic tissues were performed every 1 or 2 weeks. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid. Other conservative treatment included daily nasopharynx rinsing with 2% aquae hydrogeniidioxide (5-10 mL each time) or saline (50-100 mL each time) and antibiotic therapy (metronidazole or ornidazole) guided by the culture results was also performed synchronously. Intravenous nutrition and systematic antibiotic therapy were also performed if indicated and necessary. In addition, patients can receive hyperbaric oxygen therapy when conditions permit. Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery.
Primary Outcome Measure Information:
Title
The cure rate of nasopharyngeal necrosis at 3 months after enrollment
Description
The cure rate of nasopharyngeal necrosis is defined as the complete re-epithelialization of the nasopharyngeal cavity, upon nasal endoscopic examination, and the mucosa; upon MRI examination.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
The Numeric Rating Scales (NRS) of pain
Description
The Numeric Rating Scales (NRS) of pain was used to evaluate headaches level before and within 3 months after treatment. The patients were requested to rate their level of headache on a scale from 0 to 10, with 0 being none and 10 being unbearable.
Time Frame
3 months
Title
Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0) overall
Description
The quality of life was assessed per Quality of Life Questionnaire C30 (QLQ-C30).
Time Frame
up to 1 year
Title
Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&N35)
Description
The quality of life was assessed per Quality of Life Questionnaire Head and Neck Cancer-Specific Module (H&N35).
Time Frame
up to 1 year
Title
The cure rate of nasopharyngeal necrosis at 6 months after enrollment
Description
Patients who was assessed as non-healing at 3 months after enrollment would receive salvage surgery. The cure rate of nasopharyngeal necrosis is reassessed at 3 months after salvage surgery.
Time Frame
6 months
Title
Overall survival
Description
The time from the date of randomization to the date of death due to any cause in an Intent-to-Treat analysis set.
Time Frame
up to 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Received radical radiotherapy for the nasopharynx; For patients with early-stage and mid-stage nasopharyngeal necrosis diagnosed for the first time by clinical symptoms, imaging examinations and pathology. The lesions are limited to the superficial tissue of the nasopharynx and the deep tissue of each wall of the nasopharynx, regardless of the exposure of internal carotid artery invasion(ICA). For those patients with ICA exposure, vascular pretreatment (vascular embolization or bypass surgery) would be performed and reassess after 2-4 weeks of vascular treatment. The patient has signed the informed notice and is willing and able to comply with the study plan visits, treatment plans, laboratory tests and other study procedures. Exclusion Criteria: Karnofsky score ≤ 70 points or Zubrod score > 2 points; Patients with severe medical complications, insufficiency of important organs (heart, lung, liver, kidney) or neuropsychiatric disorders at the time of diagnosis. Patients with pathologically confirmed local recurrence. Cases who have received local nasal cavity and nasopharyngeal surgery in the past. Patients who cannot cooperate with regular follow-up due to psychological, social, family and geographical reasons. Other patients who are considered unsuitable for inclusion by the treating physician.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mingyuan Chen, MD
Phone
+86 13903052650
Email
chenmy@sysucc.org.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mingyuan Chen, MD
Organizational Affiliation
Sun Yat-sen University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510060
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ming-Yuan Chen, MD,PhD
Phone
86-20-8734-2422
Email
chenmy@sysucc.org.cn
Facility Name
The First Affiliated Hospital, Sun Yat-Sen University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510080
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wei-Ping Wen, MD, PhD
Phone
86-13802966937
Email
wenwp@mail.sysu.edu.cn
Facility Name
The Fifth Affiliated Hospital of Guangzhou Medical University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510700
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jian-Zhong Zhang, MD
Phone
86-15820279737
Email
525567166@qq.com
Facility Name
The First Hospital of Nanchang
City
Nanchang
State/Province
Jiangxi
ZIP/Postal Code
330000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mingyuan Chen
Phone
13903052650
Email
chenmy@sysucc.org.cn

12. IPD Sharing Statement

Learn more about this trial

A Randomized Controlled Clinical Trial of Surgery Versus Conservative Treatment for Mild and Moderate-grade Nasopharyngeal Necrosis

We'll reach out to this number within 24 hrs